Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>>NEW! Download now...

Unigene Ends China Peptide JV; Will Out-License Technology

publication date: Jun 13, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Unigene Laboratories, a US company that develops and makes peptide-based drugs, has closed out an eleven-year-old China JV. Unigene owned a 45% stake in Unigene Biotechnology Co., Ltd., which it will sell to its partner China Pharmaceutical Group Limited for $1 million, the amount of its original investment. In Q1 of 2011, Unigene recorded a $300,000 loss from the JV. More details....

Stock Symbol: (OTCBB: UGNE)

This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events


BioPacific Conference 2012
June 2, 2012
California, USA

  China Forum 2012
  November 11, 2012
Hamburg, Germany

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners